What advancements in our understanding of hematopoietic stem cell differentiation can be combined with practical developments in novel processing and storage technologies to develop the next generation of transfused blood therapeutics?
There is a dearth of tools to evaluate the efficacy of transfused blood products, although this is the most commonly employed therapeutic procedure in the US. There is also no financial incentive to develop the next generation of transfused blood products. This may be in part due to a lack of appreciation in the clinical setting for the reduced safety and efficacy profiles of the current products --as compared to what could potentially be provided. Another hurdle relates to the potential difficulty in retaining a safe base of returning blood donors as demand for current blood products is decreasing in the face of the potential adverse effects on morbidity/mortality that appear to be associated with liberal use of current blood therapeutics.